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Abstract
Colorectal cancer is one of the most prevalent cancers of humans. To experimentally investigate this
common disease, numerous murine models have been established. These models accurately
recapitulate the molecular and pathological characteristics of human colorectal cancer including
activation of MYC, which has recently been suggested to be a key mediator of colorectal cancer
development. This review focuses on the variety of murine models of human colorectal cancer that
are available to the research community and on their use to identify common and distinct
characteristics of colorectal cancer.
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Introduction
Colorectal cancer (CRC) is expected to account for approximately 149,000 new cases and
50,000 deaths in the United States in 2008 (American Cancer Society statistics). Although
overall five-year survival rates for CRC increased between 1975 and 2003, nearly 90% of
individuals live longer than five years if diagnosis with localized CRC but only 10% if
diagnosed with metastatic disease. A major clinical challenge that will improve survival from
CRC is early detection. Similarly, improved treatments for metastatic CRC are needed for those
cases not detected early. New approaches for CRC detection and treatment should be
accelerated through insights gained from studying current and future murine models of human
CRC.
Many genetic and carcinogen-based murine models have been developed that recapitulate
human CRC through alteration of a variety of signaling pathways (Table 1). Most CRC models
have been generated by mutating murine orthologs of human CRC genes or by discovering
models that spontaneously develop cancers during unrelated studies. Two of the most highly
studied signaling pathways implicated in human CRC are the WNT/CTNNB1 (wingless-
related MMTV integration site/beta-catenin) and TGFB (transforming growth factor beta)
pathways. The most commonly used models perturb the WNT/CTNNB1 (wingless-related
MMTV integration site/beta-catenin) signaling pathway. Components of the WNT/CTNNB1
signaling pathway, originally discovered in Drosophila (Nüsslein-Volhard and Wieschaus
1980), are dysregulated in the majority of human CRCs. The predominant initiating mutation
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in human CRC occurs in the gene encoding the adenomatous polyposis coli (APC) tumor
suppressor (Powell et al. 1992). Loss of APC function in the presence of active WNT signaling
results in increased nuclear levels of the transcriptional co-activator CTNNB1. This in turn
activates transcription of pro-cell cycle molecules like JUN resulting uncontrolled cell division
(Mann et al. 1999).
The second most widely studied pathway implicated in the progression of CRC is the TGFB
pathway. Upon activation of TGFB receptors (TGFBR1, 2 and 3), intracellular SMAD2 and
SMAD3 signal mediators become phosphorylated, bind to SMAD4 and translocate to the
nucleus where the complex interacts with other transcription factors to induce down stream
targets (Blobe et al. 2000). In the normal colonic epithelium and in early stages of
tumorigenesis, TGFB functions as a tumor suppressor by inhibiting the cell cycle through up-
regulation of CDNK1A and CDNK2B coding for cyclin-dependent protein kinase inhibitors
(Derynck et al. 2001). Unlike the WNT/CTNNB1 pathway, perturbation of TGFB signaling
is a later event in the process of carcinogenesis; up-regulation of this pathway is associated
with increased tumor invasion and metastasis (Grady et al. 1998).
Although CRCs are heterogeneous, similarities across CRCs with different etiologies and
between species are becoming apparent. Comparison of WNT and non-WNT mediated murine
models implicated MYC as a key mediator of CRC, thereby linking seemingly independent
pathways (Hanada et al. 2006; Kaiser et al. 2007; Rigby et al. 2007; Sansom et al. 2007). A
similar role for MYC during human CRC development is also suggested from its widespread
up-regulation in human CRCs (Hanada et al. 2006; Kaiser et al. 2007; Rigby et al. 2007;
Sansom et al. 2007). Although murine models have been established that model the early stages
of CRC, less progress has been achieved in establishing models that accurately recapitulate the
later stages of invasion and metastasis.
In keeping with the goal of providing a concise narrative, we have chosen to highlight a handful
of pertinent examples of murine models which have provided insight into the mechanisms of
CRC development and that hold promise in informing clinical intervention of human CRC.
WNT pathway-mediated models of CRC
APC models—The ApcMin (multiple intestinal neoplasia allele of the adenomatosis polyposis
coli gene) mouse model of human familial adenomatous polyposis (FAP) is the most widely
used CRC model for studying tumor initiation and early progression. The ApcMin model,
originally induced and fortuitously identified in a mutagenesis program (Moser et al. 1990; Su
et al. 1992), bears one functional copy of the tumor suppressor Apc gene. Upon loss of the
remaining wildtype copy of Apc, CTNNB1 is stabilized and transported to the nucleus where
it functions as a transcriptional co-activator with the LEF/TCF family of transcription factors
to stimulate cell cycle progression (Morin et al. 1997). This loss of growth control results in
the development of tens-to-hundreds of polyps in the small intestine and a small number of
polyps in the colon, while a similar mutation in humans results in predominantly colonic polyps
(Groden et al. 1991).
Since discovery of the ApcMin allele, other mutant alleles have been described. Gene targeting
was used to generate ApcΔ716 and Apc1638 alleles that display polyp distributions similar to the
ApcMin mouse (Fodde et al. 1994; Oshima et al. 1995). However, the Apc1638 model develops
significantly fewer polyps than ApcMin, while the ApcΔ716 model develops more. Liver
metastasis has been reported using the APC1638 model, possibly due to the notably longer
lifespan of these mice compared to other Apc-mediated models.
The observation that CRC predisposition in ApcMin mice is strain dependent led to the discovery
of genetic loci called ‘Modifiers of Min’ (Mom) that modulate CRC susceptibility (Dietrich et
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al. 1993). The first Mom candidate gene cloned, secretory phospholipase A2 (Pla2g2a), was
for Mom1 (MacPhee et al. 1995). Subsequently, Mom1 was found to be more complex, with
at least two distinct genes contributing to the effect of Mom1 on ApcMin (Cormier et al.
2000). Since the discovery of Mom1, over a dozen additional Mom loci have been genetically
mapped (McCart et al. 2008).
While the genes underlying most Mom loci have not been identified, other modifiers of
ApcMin-mediated CRC have been proposed using crosses with mice carrying engineered or
spontaneous mutations in specific genes. Haploinsufficiency of the Krüppel-like factor 4
(Klf4) transcription factor or reduction in EGFR activity using the Egfrwa2 hypomorphic allele
combined with loss of Apc enhances and suppresses, respectively, multiplicity in the small
intestine and colon while showing no role in subsequent tumor progression (Ghaleb et al.
2007; Roberts et al. 2002; Torrance et al. 2000). In contrast, ApcMin mice carrying mutations
in the Pten tumor suppressor gene or the Ephb2 gene for a guidance receptor show enhanced
tumor progression (Batlle et al. 2005; Shao et al. 2007). Loss of Ephb2 in mice also coincides
with a shift from small intestinal adenomas to advanced colon carcinomas, potentially
providing clues to the disparity in tumor distribution between humans with FAP and mice
carrying ApcMin (Batlle et al. 2005).
Although Apc mutant mice have been invaluable in modeling human CRC, there remain several
aspects of the human disease that are not recapitulated well with these models. Rodent
colonoscopy, a technique gaining in importance since it permits longitudinal studies of colon
tumors (Becker et al. 2006), is not well suited for Apc mutant mice since they develop tumors
predominantly in the small intestine. Additionally, Apc mutant mice rarely develop metastases
to distant organs, which is the most clinical important aspect of human CRC.
The generation of gene-specific mutations in rat by N-ethyl-N-nitrosourea (ENU) mutagenesis
provides a new avenue for modeling human CRC (Zan et al. 2003). Recently, the Pirc
(polyposis in rat colon) rat model of human CRC was generated that has a mutation in Apc
(Amos-Landgraf et al. 2007). Unlike the ApcMin mouse model where the incidence of colon
tumors is low, the Pirc model develops colon tumors with 100% incidence by four months of
age. The Pirc model opens opportunities to perform experimental studies that are difficult in
mice. Apc mutant mice can develop invasive cancer but typically have shortened life spans due
to intestinal blockage (Boivin et al. 2003). Conversely, rats are less susceptible to intestinal
blockage by tumors because of their larger intestinal diameters. In rats of at least six months
of age, twenty percent of tumors in the Pirc model become invasive (Amos-Landgraf et al.
2007). Although no distant metastases were reported in the initial analysis of the Pirc model,
metastasis of CRCs to the liver has been reported in a rat azoxymethane (AOM) carcinogen
model (Nordlinger et al. 1991).
Mismatch repair (MMR) deficient models—Hereditary non-polyposis colon cancer
(HNPCC) is an inherited condition in which inactivation of one of several DNA mismatch
repair (MMR) genes, like MLH1, MSH2, MSH6, and PMS2, result in defective DNA repair
(Lynch and de la Chapelle 2003). In humans this leads to the development of a variety of
cancers including that of the colon, endometrium, ovary, and stomach (Lynch and de la
Chapelle 2003). A number of mutant mouse lines have been generated to model the loss of
function of MMR genes in humans. Mice deficient for Mhl1, Msh2 and Msh6 develop cancers
of the stomach, small intestine and colon. However, due to the inherent nature of defective
MMR machinery, these mice also develop cancers of the lymphatic system, skin, cervix and
lung (Edelmann et al. 2000; Edelmann et al. 1999; Edelmann et al. 1997; Reitmair et al.
1996).
Uronis and Threadgill Page 3













Analysis of MMR deficient mice carrying one functional copy of Apc showed that loss of
normal MMR results in a high percentage of Apc-inactivating mutations and an elevated
frequency of tumor development (Kuraguchi et al. 2001; Reitmair et al. 1996). Mice deficient
for Mlh1 and heterozygous for the Apc1638N allele have a 40-fold increase in stomach and colon
tumors compared to Apc1638N mice alone (Edelmann et al. 1999). Similarly, mice lacking
Msh2 have accelerated development of tumors in ApcMin mice, with increased colon adenoma
number and size suggesting roles for MSH2 in both tumor initiation and progression. Although
loss of Msh3 does not lead to increased cancer predisposition until late in life, loss of Msh3
and Msh6 together results in an increase in gastrointestinal tumors at a much younger age,
similar to mice deficient for either Mlh1 or Msh2 (Edelmann et al. 2000).
Carcinogen-induced models—While genetic models have proven useful in the
investigation of cancer mechanisms, particularly for familial cancers such as FAP or HNPCC,
most human CRCs are non-familial and occur sporadically. The colon-specific carcinogen
dimethylhyrdrazine (DMH), as well as the down-stream metabolite AOM, has proven useful
in the investigation of the molecular mechanisms underlying the development of non-familial
CRCs (Druckrey et al. 1967). Mice exposed to DMH or AOM develop colorectal tumors that
accurately recapitulate pathologies seen in human CRC (Kaiser et al. 2007; Uronis et al.
2007). Consistent with the ApcMin model, AOM-induced tumors result from activation of the
WNT/CTNNB1 pathway (Takahashi et al. 2000). Unlike Apc-mediated models, AOM-induced
tumors are primarily caused by mutations in Ctnnb1, which results in ubiquitination-resistant
CTNNB1 and development of colorectal adenomas with increased expression of the key cell
cycle regulators cyclin D1 (Ccnd1) and Myc (Kaiser et al. 2007; Wang et al. 1998).
Similar to the Apc-based models, modifier loci have also been identified using the DMH or
AOM carcinogen models. Ptprj (a receptor-type protein tyrosine phosphatase) was shown to
modify susceptibility to DMH (Ruivenkamp et al. 2002), although the significance of the
orthologous gene in human CRC has not be elucidated. Although no germline PTPRJ mutations
have been reported, PTPRJ frequently shows loss of heterozygosity in human colon cancers
(Ruivenkamp et al. 2002). Additionally, Pref1, up-regulated in response to AOM in the distal
colon of tumor susceptible A/J mice but not resistant AKR/J mice, was identified using the
AOM carcinogen model (Dong et al. 2004). A direct link to WNT/CTNNB1 signaling was
suggested through a putative CTNNB1/TCF response element in the promoter of Pref1
(Ruivenkamp et al. 2002).
More recently, the AOM model was used to investigate the etiology of CRCs with distinct
morphologies. CRCs with flat morphologies more frequently escape detection during routine
colonoscopies than their larger polypoid counterparts, and with this realization have become
increasingly apparent in recent years (Owen 1996; Saitoh et al. 2001; Soetikno et al. 2006;
Soetikno et al. 2008; Speake et al. 2007). The AOM model was used to show that flat and
polypoid tumors arise independently, despite having a similar mutational spectrum (Uronis et
al. 2007).
Non-WNT pathway-mediated models of CRC
TGFB models—The transforming growth factor beta (TGFB) signaling pathway functions
in a variety of cellular processes including differentiation, growth suppression, deposition of
extracellular matrix and apoptosis. CRCs often acquire resistance to TGFB signaling and at
later stages of cancer progression, express increased levels of TGFB promoting invasion and
metastasis (Blobe et al. 2000).
Several TGFB pathway-associated models have been used to dissect the complex role of this
pathway during CRC development. Tgfb1 deficient mice die around three weeks of age due to
extensive inflammation (Kulkarni et al. 1993; Shull et al. 1992). However, on a Rag2 deficient
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background, lacking functional B and T-cells, Tgfb1 deficient mice survive until adulthood
(Diebold et al. 1995; Engle et al. 1999). Mice deficient for both Tgfb1 and Rag2 rapidly develop
carcinoma of the cecum and colon suggesting that inflammation in combination with loss of
TGFB1 results in predisposition to cancer (Engle et al. 1999). Interestingly, CRCs do not form
with Tgfb1 deficiency unless specific bacterial pathogens are present to induce inflammation
(Maggio-Price et al. 2006). Mutations in Smad2 and Smad4, but not Smad3, have been reported
to occur in human CRCs (Eppert et al. 1996; Takagi et al. 1996; Thiagalingam et al. 1996).
Smad2 and Smad4 deficient mice are embryonic lethal, while Smad3 deficient mice are viable
and develop highly invasive CRC, which metastasizes to lymph nodes by four-to-six months
of age (Zhu et al. 1998). Apc is not lost in TGFB-mediated tumors, nor do they display nuclear
localization of CTNNB1 suggesting the existence of non-WNT/CTNNB1-mediated
mechanism for tumor initiation (Kaiser et al. 2007). Consistent with current models of CRC
and with the growth suppressive role of TGFB, mice deficient for Smad3 or heterozygous for
a Smad4 mutant allele combined with mutant Apc develop an increased incidence of invasive
carcinoma of the distal colon (Sodir et al. 2006; Takaku et al. 1998).
Inflammation-mediated models—The inflammatory diseases ulcerative colitis (UC) and
Crohn's Disease, collectively termed inflammatory bowel disease (IBD), result in chronic
inflammation of the colon and predisposition to the development of CRC (Itzkowitz and Harpaz
2004; Itzkowitz and Yio 2004). In mice the role of chronic inflammation in CRC was
demonstrated by the discovery that prolonged administration of dextran sulfate sodium (DSS)
results in chronic colitis and formation of high-grade dysplasia (Okayasu et al. 1990). A single
dose of AOM followed by administration of DSS enhances tumor development and progression
(Tanaka et al. 2003). The AOM/DSS model was used recently to show that deficiency for
Sigirr (single immunoglobulin and toll-interleukin 1 receptor domain) increases susceptibility
to CRC (Wald et al. 2003; Xiao et al. 2007). Similar to Tgfb1 deficient mice, bacteria-induced
inflammation is probably important for SIGIRR-associated cancer.
The AOM/DSS model has also been used to demonstrated the importance of the JAK/STAT
(Janus kinase/signal transducers and activators of transcription) and NFKB (nuclear factor of
kappa light chain gene enhancer in B-cells) pathways for inflammation-mediated CRC (Wirtz
and Neurath 2007). Consistent with a role for the JAK/STAT pathway, loss of Socs1 and
Socs3 (suppressors of cytokine signaling) expression results in increased activation of STAT1,
STAT3 and NFKB and development of colorectal tumors (Hanada et al. 2006; Rigby et al.
2007). A direct link between SOCS signaling and Myc exists since AOM/DSS-induced
adenocarcinomas from Socs1 deficient mice have increased levels of nuclear CTNNB1 and
Myc expression when compared to tumors from Socs1 wildtype mice (Hanada et al. 2006).
Intestinal epithelium-specific deficient for Socs3 does not result in chronic inflammation or
development tumors. However, when treated with AOM/DSS, these mice develop colon
tumors preceded by inflammation suggesting that Socs3 expression in neighboring stroma may
be required to suppress chronic inflammation and subsequently tumor promotion (Hanada et
al. 2006; Rigby et al. 2007). While colorectal tumors from Socs3 deficient mice have not been
shown to display high levels of nuclear CTNNB1 as is seen in tumors from Socs1 deficient
mice, Socs3 deficiency has been shown to result in increased Myc expression in mammary
tissue (Sutherland et al. 2006).
MYC as a central mediator of CRC
Recent evidence suggests that MYC functions as a global mediator of the oncogenic process,
linking together a seemingly heterogeneous pool of molecular mechanisms underlying cancer
development (Fig. 1) (Knoepfler 2007). The discovery that deletion of Myc rescues Apc
deficiency elucidated a potential role of MYC as a key mediator of WNT/CTNNB1-initiated
CRC (Sansom et al. 2007). Additionally, available evidence suggests that MYC is also involved
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in mediating non-WNT/CTNNB1-initiated colorectal cancers. Although WNT/CTNNB1 and
non-WNT/CTNNB1-mediated CRCs can be discriminated by unique gene expression
signatures, all tumors from both classes display increased Myc expression (Kaiser et al.
2007). Myc is a direct transcriptional target of the WNT/CTNNB1 pathway, while TGFB
signaling is associated with Myc repression through SMAD3 binding to a repressive SMAD
binding element (RSBE) within the Myc promoter (Frederick et al. 2004).
A variety of genetic and carcinogen-induced murine models have provided important reagents
for investigating the complexity of human CRC. While each model has provided unique
insights into human CRC, it is becoming increasingly apparent that seemingly independent
pathways converge upon similar transforming genes. Numerous lines of evidence indicate
Myc as a central mediator of CRC, perhaps through its role in chromatin remodeling (Knoepfler
2007; Knoepfler et al. 2006). Mouse models have been used to show that decreased Myc
expression leads to reduced numbers of CRCs (Yekkala and Baudino 2007), a result confirmed
by Myc inhibition in human CRCs (Hao et al. 2008; Zhang et al. 2009).
While the exact role of MYC in the development of CRC is not fully understood, it is clear
that increased attention on the role of MYC during CRC development and progression warrants
further study and that murine models of human CRC will be essential to fully understand MYC
function. Similarly, the development of new murine models with characteristics of metastatic
CRC, possibly generated using new technologies like transposon-based screens in existing
models (Starr et al. 2009), should greatly accelerate the discovery of new therapies to treat
advanced human CRCs.
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Fig. 1. Molecular pathways associated with colorectal cancer
Two major pathways, WNT and TGFB, converge in the nucleus to effect Myc expression.
Murine models for human CRC have been developed by genetically altering many components
of these two pathways. *, Modifiers of cancer initiation and progression.
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